The Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis

Background: Tocilizumab has demonstrated optimal efficacy and safety in patients with rheumatoid arthritis (RA) from clinical trials. However, the risk of hepatitis B virus reactivation (HBVr) in these patients remains uncertain because patients with underlying HBV have been excluded in phase III st...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Ping-Hung Ko, Meng Hsuan Kuo, I-Ting Kao, Chen-Yi Wu, Chih-Wei Tseng, Shih-Chieh Shao
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2024-01-01
Serie:	Viruses
Soggetti:	HBV reactivation hepatitis flare-up rheumatoid arthritis tocilizumab
Accesso online:	https://www.mdpi.com/1999-4915/16/1/78
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!